Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 15Neoplasms 10Carcinoma, Renal Cell 8Carcinoma, Hepatocellular 8Melanoma 7Carcinoma, Non-Small-Cell Lung 7Endometrial Neoplasms 6Thyroid Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Thyroid Cancer, Papillary 3Stomach Neoplasms 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Adenocarcinoma, Follicular 3Ovarian Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Glioma 2Carcinoma, Transitional Cell 2Carcinoma 2Biliary Tract Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1

Interventions

aldesleukin 15Cyclophosphamide 15fludarabine phosphate 12fludarabine 11Interleukin-2 10Nivolumab 6Ipilimumab 6Temozolomide 5pembrolizumab 3Fluorouracil 3trametinib 2sonidegib 2dabrafenib 2binimetinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Sodium Chloride 2Sirolimus 2Radiotherapy 2Radiation 2Peptides 2HhAntag691 2Gefitinib 2Dacarbazine 2Cyclosporine 2Cetuximab 2Capecitabine 2veliparib 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Skin Neoplasms × lenvatinib × Clear all
NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
26 enrolled 9 charts
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡